top of page
Executive Spotlights

Alumis Announces $259M Series C Financing

South San Francisco, CA, March 6, 2024 (VC News Daily) -- Alumis Inc., a pioneering clinical-stage biopharmaceutical enterprise dedicated to revolutionizing patient care in immune-mediated diseases through precision oral therapies, has disclosed an expanded Series C financing totaling $259M. This funding round, spearheaded by Foresite Capital alongside fresh investors Samsara BioCapital and venBio Partners, showcases robust confidence in Alumis' innovative approach.

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page